Data Using Carotid Protection Devices Could Drive Shift From Surgery to Stenting

The successful preliminary results of the SAPPHIRE trial--the first study comparing carotid stenting using embolic protection to surgery for carotid artery disease--may drive a shift from surgery to stenting, and may increase adoption of embolic protection devices.

While coronary angioplasty (PTCA) with stenting revolutionized the treatment of coronary artery disease (CAD) and quickly gained widespread adoption, replacing coronary artery bypass graft (CABG) surgery for many patients, carotid angioplasty with stenting remains in its infancy. Twenty years after angioplasty revolutionized coronary revascularization, physicians generally prefer to stick with the surgical gold standard for carotid artery disease, carotid endarterectomy (CEA)—a traumatic but generally successful surgical procedure. That could begin to change, however, with the announcement, at this year's American Heart Association (AHA) meeting held in Chicago in November, of successful preliminary results from the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) clinical trial.

Driving this shift from surgery to carotid angioplasty is the successful development of embolic protection devices that diminish the likelihood...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

German Health Researchers Prep for Possible Disruptions to PubMed, ClinicalTrials.gov

 

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.

Hip Resurfacing For Women: Embody Orthopaedic Awarded CE Mark For H1 Implant

 

The ceramic device, designed to reduce complications, will be exclusively distributed by Zimmer Biomet and initially available in 30 hospitals, with broader European access expected by 2026.

Even ‘Small’ Leaks After Left Atrial Appendage Occlusion Raises Stroke Risk, Study Finds

 

A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.

More from R&D

Philips Announces Major Investment In US Manufacturing And Expansion Of Pennsylvania Facility

 

Philips says the expansion of its facility in Reedsville, PA, will not only boost its capacity to produce AI-enabled ultrasounds that are used in hospitals across the US but will also create 120 well-paying jobs.

UK’s Dementia Trials Accelerator Works To Fast-Track Recruitment

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

Nyxoah Launches FDA-Cleared Genio System For OSA As Rival Inspire Files Patent Suit

 
• By 

After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.